drugset / Trial / NCT02285465

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP3700 in Healthy Subjects

NCT02285465

Phase 1 Withdrawn Astellas Pharma Europe B.V.
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of ascending multiple oral doses of ASP3700 in healthy subjects.

Timeline

Start
2014-11
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ASP3700 Unknown Oral

Indications

No indication recorded.